Cantor Fitzgerald Cuts Rating and Price Target Ventrus Biosciences (VTUS); Phase III Trial Misses; New Exit Strategy Potential Sale
Tweet Send to a FriendGet Alerts VTUS Hot Sheet
Price: $2.76 --0%
Rating Summary:
7 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 0
Rating Summary:
7 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 0
Trade VTUS Now!
Cantor Fitzgerald downgraded Ventrus Biosciences (NASDAQ: VTUS) from Buy to Hold with a price target of $5.50 (from $30.00).
Analyst, Irina Rivkind, said, "Ventrus announced that its pivotal Phase III trial in 603 hemorrhoid patients failed to meet both primary and secondary endpoints. We previously viewed this drug as the key value driver for the company. Management believes that it has sufficient cash to take its second Phase III drug in anal fissures (VEN-307) all the way through to NDA approval and will also start early formulation work in its fecal incontinence drug (VEN-308). We believe that the company will need additional dilutive financing along the way, especially if it plans to build a commercial infrastructure in 2015."
Rivkind said that the company's remaining assets are relatively small. Overall, the Phase III compound for anal fissures (topical diltiazem dosed TID) could reach $75M/year. The alternative is a sale of the company as a potential exit strategy.
For an analyst ratings summary and ratings history on Ventrus Biosciences click here. For more ratings news on Ventrus Biosciences click here.
Shares of Ventrus Biosciences closed at $12.26 yesterday, with a 52 week range of $6.64-$16.17.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Irina Rivkind, said, "Ventrus announced that its pivotal Phase III trial in 603 hemorrhoid patients failed to meet both primary and secondary endpoints. We previously viewed this drug as the key value driver for the company. Management believes that it has sufficient cash to take its second Phase III drug in anal fissures (VEN-307) all the way through to NDA approval and will also start early formulation work in its fecal incontinence drug (VEN-308). We believe that the company will need additional dilutive financing along the way, especially if it plans to build a commercial infrastructure in 2015."
Rivkind said that the company's remaining assets are relatively small. Overall, the Phase III compound for anal fissures (topical diltiazem dosed TID) could reach $75M/year. The alternative is a sale of the company as a potential exit strategy.
For an analyst ratings summary and ratings history on Ventrus Biosciences click here. For more ratings news on Ventrus Biosciences click here.
Shares of Ventrus Biosciences closed at $12.26 yesterday, with a 52 week range of $6.64-$16.17.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: Crash in American Electric Power (AEP) & NextEra Energy (NEE) Adds to Jitters
- UPDATE: GameStop (GME) Slides Into Close
- SHAREHOLDER ALERT: Pomerantz Law Firm Has Filed a Class Action Against Ventrus Biosciences, Inc. and Certain Officers -- VTUS
Create E-mail Alert Related Categories
Downgrades, FDA, Trader TalkRelated Entities
Cantor Fitzgerald
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
